Jazz Pharmaceuticals Quarterly Income Statement
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Jazz Pharmaceuticals generated $1.21 billion in revenue, up 15.5% from the same quarter a year earlier. Net income was $192.8 million, for a net margin of 16.0% versus a median of 17.0% in the prior 5 quarters. Operating margin was 20.5%.
Diluted earnings per share came in at $2.78.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 1.07B | 1.20B | 1.13B | 1.05B | 897.80M | 1.09B | 1.05B | 1.02B | 901.98M | 1.01B | 972.14M |
| Revenue growth (YoY) | +15.55% | +19.06% | +10.09% | +6.74% | +2.14% | -0.46% | +7.53% | +8.52% | +6.95% | +1.03% | +4.10% | +3.35% |
| Research & Development | 207.50M | 196.00M | 213.91M | 198.20M | 189.90M | 180.70M | 240.50M | 199.92M | 220.73M | 222.85M | 216.61M | 234.40M |
| Selling, General & Admin | 389.20M | 352.70M | 406.21M | 530.65M | 358.40M | 514.00M | 369.29M | 325.77M | 338.52M | 351.71M | 396.03M | 308.31M |
| Operating Income | 248.20M | 336.60M | 254.53M | 57.51M | -686.40M | -55.90M | 190.77M | 260.21M | 199.44M | 66.21M | 122.50M | 172.39M |
| Pretax Income | 211.00M | 299.20M | 208.47M | 9.04M | -735.60M | -109.80M | 133.22M | 200.81M | 137.93M | -1.60M | 61.53M | 99.52M |
| Income Tax | 18.10M | 6.10M | 4.96M | -242.42M | -17.20M | -17.80M | -57.91M | -14.53M | -30.65M | 11.67M | -33.09M | -47.18M |
| Net Income | 192.80M | 293.10M | 203.45M | 251.41M | -718.50M | -92.50M | 191.12M | 215.06M | 168.57M | -14.62M | 94.15M | 146.82M |
| Net Income growth (YoY) | — | — | +6.45% | +16.91% | -526.24% | — | +102.98% | +46.48% | +61.40% | -121.06% | — | — |
| EPS (Basic) | 3.05 | 4.73 | 3.28 | 4.14 | -11.74 | -1.52 | 3.11 | 3.50 | 2.68 | -0.23 | 1.50 | 2.33 |
| EPS (Diluted) | 2.78 | 4.43 | 3.34 | 4.08 | -11.74 | -1.52 | 2.97 | 3.42 | 2.49 | -0.23 | 1.40 | 2.14 |
| Shares Outstanding (Basic) | 63.20M | 61.90M | — | 60.70M | 61.20M | 61.00M | — | 61.41M | 62.88M | 62.54M | — | 63.11M |
| Shares Outstanding (Diluted) | 69.40M | 66.10M | — | 61.61M | 61.20M | 61.00M | — | 63.17M | 69.63M | 62.54M | — | 71.29M |
| EBITDA | 257.30M | 345.70M | 263.96M | 67.42M | -674.50M | -45.50M | 200.28M | 267.99M | 207.25M | 73.86M | 130.15M | 180.07M |
| Operating Margin | 20.54% | 31.49% | 21.25% | 5.11% | -65.64% | -6.23% | 17.53% | 24.67% | 19.48% | 7.34% | 12.11% | 17.73% |
| Net Margin | 15.96% | 27.42% | 16.98% | 22.33% | -68.71% | -10.30% | 17.56% | 20.38% | 16.46% | -1.62% | 9.30% | 15.10% |
This table shows 12 quarterly periods of Jazz Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, gross profit, operating expenses. Values in USD; B = billions, M = millions. Fiscal periods follow JAZZ's reporting calendar. What is a income statement?